The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature
American Journal of Hypertension · 24.02.2023 · 36 (3) · 135-143
DOI: 10.1093/ajh/hpac124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, online erschienen am 04.11.2022. Verfasst von Panagiotis I Georgianos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hyperkalemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Steroidal mineralocorticoid-receptor-antagonists (MRAs), such as spironolactone and eplerenone, are guideline-directed therapies in patients with heart failure with reduced ejection fraction or resistant hypertension. However, the associated risk of hyperkalemia and hormonal side effects limit their broad use and downstream cardiorenal protection in high-risk patients with type 2 diabetes mellitus (T2DM) and moderate-to-advanced chronic kidney disease (CKD). The critical unmet need to improve long-term cardiorenal outcomes in such patients with CKD has sparked considerable efforts to the discovery and development of a new class of compounds. Finerenone is a novel, nonsteroidal MRA that has recently received regulatory approval with the indication of cardiorenal protection in patients with CKD associated with T2DM. Two landmark phase 3 clinical trials, FIDELIO-DKD and FIGARO-DKD, demonstrated that among patients with T2DM and a broad spectrum of CKD, finerenone reduced the risk of “hard” cardiovascular and kidney failure outcomes as compared with placebo, with a minimal risk of hyperkalemia. Subgroup analyses of these trials also provided preliminary evidence that the efficacy and safety profile of finerenone was similar and irrespective of background therapy with other guideline-directed therapies, such as sodium-glucose co-transporter type 2 (SGLT-2) inhibitors and glucagone-like peptide 1 receptor agonists. Whether the combination of finerenone with a SGLT-2 inhibitor is more beneficial in patients with T2DM and CKD as compared with either therapy alone is a crucial research question that is currently under investigation in an ongoing clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
ORCID-Profile: Panagiotis I Georgianos, Rajiv Agarwal
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Georgianos, P. I., & Agarwal, R. (2023). The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. American Journal of Hypertension, 36(3), 135-143. https://doi.org/10.1093/ajh/hpac124
Vancouver
Georgianos PI, Agarwal R. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. American Journal of Hypertension. 2023;36(3):135-143. doi:10.1093/ajh/hpac124
BibTeX
@article{Georgianos2023,
author = {Georgianos, Panagiotis I and Agarwal, Rajiv},
title = {The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature},
journal = {American Journal of Hypertension},
year = {2023},
volume = {36},
number = {3},
pages = {135--143},
doi = {10.1093/ajh/hpac124}
}
EUVIMED